GLPwatch
Treatment evaluation of liraglutide in type 2 diabetes.
Expert Opin Biol Ther · 2012
Last updated 2026-05-28Liraglutide is a once-daily injectable drug for type 2 diabetes that works by activating GLP-1 receptors, improving blood sugar control and helping with weight loss. Clinical trials have shown it reduces blood sugar and body weight more than placebo, with safety data also reviewed.
AI summary of the abstract below.
| Journal | Expert Opin Biol Ther, 2012 |
|---|---|
| Citations | 6 |
| Relative citation ratio | 0.22 |
| NIH percentile | 14 |
| Molecules | liraglutide |
| Conditions studied | Type 2 Diabetes |
Abstract
Liraglutide is a Glucagon like Peptide-1 (GLP-1) receptor agonist, which stimulates GLP-1 receptors and consequently leads to various cardio-metabolic and glycemic improvements in individuals with Type 2 Diabetes Mellitus (T2DM). It is administered once daily as a subcutaneous injection and has been extensively studied in randomized placebo and active comparator studies demonstrating favorable effects on glycemic control and weight reduction. This short review summarizes the role and practical use of this agent in the context of efficacy and safety information obtained during clinical trials.
Verbatim abstract via PubMed 22897447 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.